Immunologic Factor
gemtuzumab ozogamicin
[ gem-too-zoo-mab oh-zoh-ga-mih-sin ]
Brand Names:
Mylotarg
Effect:
Decreased DNA Integrity; Increased Cellular Death
May Treat:
Leukemia, Myeloid, Acute;
Leukemia, Myelomonocytic, Acute
More Information:
Definitions related to gemtuzumab ozogamicin:
-
A monoclonal antibody combined with a toxic substance that is used to treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Mylotarg is a type of antibody-drug conjugate.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
-
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)NCI ThesaurusU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> G
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.